Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PAXIL CR vs LEXAPRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Paroxetine is a selective serotonin reuptake inhibitor (SSRI). It potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Posttraumatic stress disorder,Premenstrual dysphoric disorder (off-label),Hot flashes (off-label)
Major depressive disorder,Generalized anxiety disorder,Obsessive-compulsive disorder (off-label),Panic disorder (off-label),Post-traumatic stress disorder (off-label),Premenstrual dysphoric disorder (off-label)
12.5-37.5 mg orally once daily in the morning; initial dose 12.5 mg/day, titrate by 12.5 mg/day at intervals of at least 1 week to maximum 50 mg/day.
10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.
The terminal elimination half-life of paroxetine (PAXIL CR) is approximately 15-20 hours. This supports once-daily dosing and requires about 5-7 days to reach steady-state concentration.
27-32 hours (mean ~30 h); steady state reached in ~1 week; linear kinetics at therapeutic doses.
Extensively metabolized in the liver primarily via cytochrome P450 enzyme CYP2D6. Paroxetine is a potent inhibitor of CYP2D6. Metabolites are less active and are excreted in urine and feces.
Primarily hepatic via CYP3A4 and CYP2C19; active metabolite S-desmethylcitalopram.
Renal excretion accounts for approximately 64% of the administered dose, with 2% as unchanged parent drug and the remainder as metabolites. Fecal excretion accounts for about 36%, mostly as metabolites. Less than 1% is excreted in bile.
Primarily renal (approx. 80% as metabolites, 8% as unchanged drug); biliary/fecal elimination accounts for ~15%.
Approximately 93-95% bound to plasma proteins, primarily alpha-1-acid glycoprotein and albumin.
Approximately 56% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein).
Apparent volume of distribution (Vd/F) is approximately 3-28 L/kg, with an average of about 13 L/kg. This wide distribution indicates extensive tissue partitioning, with brain concentrations several times higher than plasma.
12-26 L/kg (mean ~20 L/kg); extensive extravascular distribution consistent with high lipophilicity.
Oral bioavailability of PAXIL CR is about 30% due to first-pass metabolism, but is lower than the immediate-release formulation (50%). Food does not significantly affect bioavailability.
Oral: approximately 80% (range 60-90%) after a single dose; food does not significantly affect absorption.
Creatinine clearance 30-60 m L/min: use lower end of dosing range (12.5 mg/day maximum). Creatinine clearance <30 m L/min: not recommended.
No dosage adjustment for mild to moderate impairment. Not recommended for severe impairment (Cr Cl <20 m L/min).
Child-Pugh Class A or B: initial dose 12.5 mg/day, maximum 25 mg/day. Child-Pugh Class C: not recommended.
For Child-Pugh class A or B: 10 mg orally once daily. Use caution in severe impairment (Child-Pugh class C); limited data.
Not approved for use in pediatric patients; safety and efficacy not established.
Adolescents 12-17 years: 10 mg orally once daily. Children <12 years: not approved.
Initial dose 12.5 mg/day; maximum 25 mg/day. Increased sensitivity to serotonin reuptake inhibition; monitor for hyponatremia and QT prolongation.
Initial 5 mg orally once daily; maximum 10 mg once daily.
Suicidality and Antidepressant Drugs: Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term trials. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Clinical worsening and suicide risk,Serotonin syndrome,Bleeding abnormalities,Activation of mania/hypomania,Seizures,Angle-closure glaucoma,Hyponatremia,Bone fractures,Discontinuation syndrome (withdrawal reactions)
Suicidality risk in young adults,Serotonin syndrome,QT prolongation,Hyponatremia,Bleeding risk,Activation of mania/hypomania,Seizure risk,Abrupt discontinuation syndrome
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Concomitant use with pimozide or thioridazine,Known hypersensitivity to paroxetine or any component of the formulation
Concurrent use of MAOIs or within 14 days of discontinuing MAOI,Concomitant use of pimozide,Hypersensitivity to escitalopram or citalopram,QT prolongation or congenital long QT syndrome (for citalopram, caution for escitalopram)
No specific food restrictions, but avoid excessive alcohol intake. Grapefruit has not been reported to interact significantly with paroxetine.
Grapefruit juice may increase escitalopram exposure; avoid concurrent use. Alcohol can potentiate central nervous system depression; limit or avoid alcohol consumption. No significant food interactions; may be taken with or without food.
First trimester: Increased risk of congenital cardiovascular malformations (primarily septal defects) and persistent pulmonary hypertension of the newborn (PPHN). Third trimester: Risk of neonatal adaptation syndrome (irritability, feeding difficulties, respiratory distress) and prolonged QT interval. Late third trimester exposure may cause serotonin syndrome in neonate.
First trimester: Epidemiologic studies have shown a small increased risk of congenital cardiac defects (primarily ventricular septal defects) with exposure, with an absolute risk of approximately 1-2%. Second/third trimester: Late pregnancy exposure may increase risk for persistent pulmonary hypertension of the newborn (PPHN) and serotonin syndrome in the neonate. Third trimester use may lead to neonatal adaptation syndrome including irritability, respiratory distress, and feeding difficulties.
Paroxetine is excreted into breast milk. M/P ratio is approximately 0.39. Milk levels vary; peak concentration occurs 2-4 hours post-dose. Most studies show no adverse effects in breastfed infants, but cases of irritability, poor feeding, and transient serotonin-like symptoms have been reported. Use caution; monitor infant for drowsiness, restlessness, and weight gain.
Escitalopram is excreted into human breast milk with a milk-to-plasma ratio (M/P) of approximately 2.0. Infant serum levels are typically low, but some cases of adverse effects such as irritability, feeding problems, and sleep disturbance have been reported. The American Academy of Pediatrics considers escitalopram compatible with breastfeeding, but caution is advised, especially in premature or compromised infants.
Paroxetine clearance may decrease in pregnancy, leading to higher plasma concentrations. However, dose adjustments are generally not routinely recommended due to limited data. Consider therapeutic drug monitoring if response is inadequate or side effects occur. The risk of birth defects with high doses (>30 mg/day) may be increased, so use lowest effective dose (12.5-37.5 mg/day CR). Avoid abrupt discontinuation; taper slowly postpartum.
Pharmacokinetic changes during pregnancy (increased volume of distribution, increased clearance) may require dose adjustments. Escitalopram clearance increases by approximately 50% in the third trimester. Dose increases may be needed to maintain efficacy, with gradual reduction postpartum to pre-pregnancy dose over 2-4 weeks. Therapeutic drug monitoring of escitalopram and its metabolite S-DCT is recommended if available, targeting trough levels of 15-80 ng/m L.
PAXIL CR (paroxetine extended-release) has a longer half-life than immediate-release, allowing once-daily dosing but requiring 3-4 weeks for steady state. Due to its potent CYP2D6 inhibition, use caution with tamoxifen (reduces active metabolite) and with other serotonergic drugs (risk of serotonin syndrome). Discontinuation syndrome is common; taper gradually. Pregnancy category D; avoid in third trimester due to risk of persistent pulmonary hypertension of the newborn (PPHN).
LEXAPRO (escitalopram) is the S-enantiomer of citalopram with less cytochrome P450 inhibition, minimizing drug interactions compared to racemic citalopram. QT prolongation risk is dose-dependent; maximum dose is 20 mg/day. Avoid co-administration with MAOIs and other serotonergic drugs due to serotonin syndrome risk. Abrupt discontinuation may cause withdrawal symptoms; taper over 1-2 weeks. Onset of therapeutic effect is 2-4 weeks. Use with caution in hepatic impairment (max dose 10 mg) and elderly patients.
Take this medication once daily, usually in the morning with or without food. Swallow the tablet whole; do not crush, chew, or divide.,It may take several weeks to feel the full benefit; do not stop suddenly as withdrawal symptoms may occur.,Avoid alcohol while taking PAXIL CR as it can increase dizziness and drowsiness.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Report any suicidal thoughts or unusual changes in mood immediately.,Do not take with MAO inhibitors (e.g., phenelzine) or within 14 days of stopping them.,Contact a healthcare professional if you experience symptoms of serotonin syndrome (fever, muscle stiffness, confusion, rapid heart rate).
Take LEXAPRO once daily, either in the morning or evening, consistently with or without food.,Do not stop taking this medication suddenly; consult your doctor for a gradual dose reduction to avoid withdrawal symptoms.,Inform your doctor of all medications you are taking, especially MAOIs (e.g., linezolid, methylene blue), other antidepressants, and blood thinners.,Avoid alcohol and grapefruit juice as they may increase side effects.,Contact your doctor immediately if you experience suicidal thoughts, serotonin syndrome symptoms (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness), or prolonged QT interval symptoms (e.g., palpitations, fainting).,It may take several weeks to feel the full benefit; continue taking as prescribed.,Monitor for worsening depression or anxiety, especially during the first few months of treatment.,If pregnant or planning to become pregnant, discuss risks with your doctor (may cause neonatal complications).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PAXIL CR vs LEXAPRO, answered by our medical review team.
PAXIL CR is a SSRI Antidepressant that works by Paroxetine is a selective serotonin reuptake inhibitor (SSRI). It potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.. LEXAPRO is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PAXIL CR and LEXAPRO depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PAXIL CR is: 12.5-37.5 mg orally once daily in the morning; initial dose 12.5 mg/day, titrate by 12.5 mg/day at intervals of at least 1 week to maximum 50 mg/day.. The standard adult dose of LEXAPRO is: 10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PAXIL CR and LEXAPRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PAXIL CR is classified as Category C. First trimester: Increased risk of congenital cardiovascular malformations (primarily septal defects) and persistent pulmonary hypertension of the newborn (PPHN). Third trimester: . LEXAPRO is classified as Category C. First trimester: Epidemiologic studies have shown a small increased risk of congenital cardiac defects (primarily ventricular septal defects) with exposure, with an absolute risk o. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.